According to a research published today in eLife, scientists have revealed how medicines can regress some fast-growing bacteria.
The findings demonstrate that fast-growing individuals in bacterial colonies have much greater levels of active ribosomes, which are protein-synthesising components within the cell. This prevents the bacteria from accumulating an essential class of antibiotics known as macrolides and thereby resisting treatment. These results might help scientists build more effective antibiotics that target this survival mechanism.
Food poisoning, pneumonia, sepsis, and other deadly disorders can all be caused by bacterial infections. While antibiotics may be used to treat them, their abuse in recent years has resulted in bacteria growing increasingly resistant to them, posing a serious danger to world health.
To be effective against infection, an antibiotic must reach its cellular target at a concentration high enough to limit bacterial growth.
"Antibiotic resistance continues to threaten the viability of current treatments. We need to understand how individual bacteria within a colony can prevent antibiotics from entering their cells, so that we can target this mechanism with new therapies," Urszula apiska, PDRA at the University of Exeter in the United Kingdom, agrees. "Most existing data around drug permeability in bacteria has been attained through measurements that either take an average result from a large population or are derived from a small number of bacteria. This means that little is known about the variability in individual drug accumulation across many single cells in a bacterial colony."
To close the gap, apiska and her colleagues hypothesized that differences in how bacteria respond to medications may be caused by differences in drug transport rates between individual cells. To do so, the researchers used a multi-analytical approach that included microfluidics-microscopy, bacteria that pose a health risk, such as E. coli, Pseudomonas aeruginosa, Burkholderia cenocepacia, and Staphylococcus aureus, and fluorescent probes derived from antibiotics developed by Dr Mark Blaskovich at the University of Queensland.This method enables the researchers to investigate the interactions between conventional antibiotics and a large number of live, individual bacteria in real time, during medication administration. The scientists gathered data that they could use to swiftly and efficiently identify individual bacteria that are antibiotic resistant by combining this strategy with mathematical modeling approaches pioneered by Prof Krasimira Tsaneva-Atanasova from the University of Exeter.
Their findings show that fast-growing individuals in a colony avoid accumulating macrolides within their cells, which contradicts current belief that sluggish cell growth is the most important factor in antibiotic resistance without genetic diversity. When compared to their slow-growing counterparts, the individuals had a considerably larger number of ribosomes before medication treatment, allowing them to avoid the drug. Ribosomes are involved in a variety of biological functions, including efflux, which is a mechanism that removes hazardous molecules from the cell, such as antimicrobial agents.
The researchers next demonstrated that chemically modifying the outer membrane of bacterial cells allows for the eradication of fast-growing variations with minimal macrolide accumulation, so boosting our battle against antibiotic resistance.
"This work reveals a hitherto unrecognised survival strategy in some members of bacterial colonies ," says Dr Stefano Pagliara, Senior Lecturer in Microfluidics at the University of Exeter in the United Kingdom. "These insights will directly benefit microbiologists and clinicians who are working on the development of more effective antibiotic therapies. In the longer term, we hope that using our novel approach in clinical settings will help inform the design of improved drugs and help us in the fight against antibiotic resistance."
.jpg)
